Beloteca, Inc. Relocates Lab & Corporate Headquarters In San Diego, California
05/12/2017
The new facility currently spans more than 3,500 square feet and will expand to over 6,000 square feet. The larger space allows Beloteca's to increase its in-house product development capabilities and hire more employees in formulation and analytical development.
Beloteca currently has an active development pipeline with more than 15 pharmaceutical products in various stages of development.
According to company officials, the unification of the headquarters and laboratories will provide increased communication and collaboration between development and the other departments resulting in more efficient development of products.
"We are excited to have found this new location as it will enable Beloteca to continue to grow and internalize development over the next several years," said Fred Defesche, CEO of Beloteca, Inc. "The new space is ideal because it allows us to acquire additional space after obtaining approval of our first products without being encumbered by excess expenses while we are in our startup phase,” he added.
Project Announcements
Nelson Brothers Expands Walker County, Alabama, Operations
05/04/2025
Kimberly-Clark Expands Aiken County, South Carolina, Distribution Operations
05/04/2025
Aerowerks Plans Gaffney, South Carolina, Manufacturing Operations
05/04/2025
Sweden-Based Troax Group Plans Portland, Tennessee, Manufacturing Operations
05/04/2025
Kimberly-Clark Corporation Plans Warren, Ohio, Manufacturing Operations
05/04/2025
Denmark-Based Novonesis Expands Salem, Virginia, Production Operations
05/04/2025
Most Read
-
Run a Job Task Analysis
Q4 2024
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
The Location Economics of Advanced Nuclear
Q1 2025
-
Why Workforce Readiness Can’t Wait
Q1 2025
-
Power, Policy, and Site Selection in 2025
Q1 2025
-
Is It Time to Start Planning for Quantum Data Centers?
Q1 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024